Covidien COV today announced the start of patient enrollment in the ev3 DEFINITIVE™ AR (Anti-Restenosis) study Imelda Hospital in Belgium with Dr. Patrick Peeters.
DEFINITIVE AR is a European pilot study designed to address the challenge of restenosis (narrowing of a blood vessel) in patients with Peripheral Arterial Disease. The study will look at the effects of treating a diseased vessel with plaque excision prior to the use of a drug-coated balloon.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in